C4BP Isoforms for Immunological Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immunological diseases such as rheumatoid arthritis and systemic lupus erythematosus require high doses and frequent administration, leading to toxicity and inefficacy, and existing therapies fail to effectively manage undesired immune system activation.
Innovation Solution
Subcutaneous administration of C4BP isoforms lacking the beta chain and polypeptides comprising the CCP6 domain, which down-regulate dendritic cell activation, are used at low doses and reduced frequencies to treat immunological diseases, preserving the CCP6 domain for tolerogenic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunosuppressive agents are used to treat immunological diseases, then immune system activation is suppressed, but high doses and frequent administration are required leading to toxicity and inefficacy
Solution Approach 1:
The patent extracts the essential functional domain (CCP6 domain of C4BP alpha-chain) required for immunomodulatory activity while removing unnecessary portions of the protein. This extraction allows using only the minimal active component, achieving therapeutic effect at low doses without the toxicities associated with conventional high-dose immunosuppressants
Solution Approach 2:
The invention applies local quality by modifying specific regions of the C4BP protein - specifically preserving the CCP6 domain while allowing variations in other domains. This localized preservation of critical functional elements maintains immunomodulatory activity while reducing overall molecular complexity and dose requirements
2Reliability
If high doses of C4BP are administered frequently to achieve therapeutic effect, then immune system activation is suppressed, but the treatment complexity and burden increase
Solution Approach 1:
The patent changes the molecular parameters of C4BP by creating truncated versions containing only the essential CCP6 domain. This parameter change in molecular structure results in enhanced potency, allowing administration at low doses (0.1-10 mg/kg) with extended intervals (once weekly or less frequently), dramatically simplifying the treatment regimen
3Reliability
If the full-length C4BP is used for treatment, then complement regulation function is maintained, but the molecule size and clearance rate increase requiring higher doses
Solution Approach 1:
The invention extracts the essential CCP6 domain from the full-length C4BP molecule, creating a minimized version that retains immunomodulatory function. This extraction reduces the molecular size and apparent clearance rate, enabling effective treatment at low doses without requiring the complete full-length protein
Data Source
AI summary
Compounds for use in the prevention and/or treatment of immunological diseases, particularly rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis, are described, characterized by the subcutaneous administration of isoforms of C4BP lacking the beta chain or polypeptides comprising the CCP6 region of the alpha chain of C4BP no more than once a week or at a dose ranging from 0.24 mg/m2 to 9.99 mg/m2. Pharmaceutical compositions comprising from 0.45 mg to 18.90 mg of these compounds for the prevention and/or treatment of these diseases are also described.